Terrence Blaschke - Durect Independent Director

DRRX Stock  USD 1.34  0.07  5.51%   

Director

Dr. Terrence F. Blaschke, M.D., is an Independent Director of DURECT Corporationrationration, since December 2006. Dr. Blaschke has served on the faculty of Stanford University since 1974 and is Professor of Medicine and Molecular Pharmacology at the Stanford University School of Medicine. He is currently a senior program officer, Global Health Discovery and Translational Science at the Bill and Melinda Gates Foundation. Dr. Blaschke held the position of Vice President of Methodology and Science at Pharsight Corporation from 2000 to 2002. Dr. Blaschke has served as an independent consultant working with a number of leading pharmaceutical and biotechnology companies. Dr. Blaschke was formerly a board member of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals, two publiclytraded companies. He has also worked as a special government employee for the U.S. Food and Drug Administration and has served as the chairman of the FDAs Generic Drugs Advisory Committee. Dr. Blaschkes medical and scientific expertise and pharmaceutical industry experience as relates to drug development are among the qualifications he brings to the Board and his service as a Director of the Company. since 2006.
Age 71
Tenure 18 years
Address 10260 Bubb Road, Cupertino, CA, United States, 95014-4166
Phone408 777 1417
Webhttps://www.durect.com

Durect Management Efficiency

The company has return on total asset (ROA) of (0.4274) % which means that it has lost $0.4274 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4881) %, meaning that it created substantial loss on money invested by shareholders. Durect's management efficiency ratios could be used to measure how well Durect manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -1.01 in 2024. Return On Assets is likely to drop to -0.71 in 2024. At this time, Durect's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 13.4 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 218.9 K in 2024.
The company currently holds 23.26 M in liabilities with Debt to Equity (D/E) ratio of 0.68, which is about average as compared to similar companies. Durect has a current ratio of 4.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Durect until it has trouble settling it off, either with new capital or with free cash flow. So, Durect's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Durect sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Durect to invest in growth at high rates of return. When we think about Durect's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Carina Olofsson23Andme Holding Co
42
Americo Romano23Andme Holding Co
58
Staffan Gavel23Andme Holding Co
67
AnnChristine Hvittfeldt23Andme Holding Co
49
Robert WilsonMadrigal Pharmaceuticals
75
Mala AnandAgilent Technologies
53
Mark PruzanskiEquillium
50
Daniel PodolskyAgilent Technologies
67
Gregory BeharSeres Therapeutics
48
Salvatore Falco23Andme Holding Co
46
Giuseppe Lettieri23Andme Holding Co
33
Tadataka YamadaAgilent Technologies
74
Arturo Testa23Andme Holding Co
37
Bala ManianEquillium
72
Paul FriedmanMadrigal Pharmaceuticals
75
George ScangosAgilent Technologies
72
Marc LavineEquillium
N/A
Roy Blom23Andme Holding Co
65
Dow WilsonAgilent Technologies
61
Heidi FieldsAgilent Technologies
60
Frederick CravesMadrigal Pharmaceuticals
72
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Durect Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people. Durect (DRRX) is traded on NASDAQ Exchange in USA. It is located in 10260 Bubb Road, Cupertino, CA, United States, 95014-4166 and employs 72 people. Durect is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Durect Leadership Team

Elected by the shareholders, the Durect's board of directors comprises two types of representatives: Durect inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Durect. The board's role is to monitor Durect's management team and ensure that shareholders' interests are well served. Durect's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Durect's outside directors are responsible for providing unbiased perspectives on the board's policies.
Simon Benito, Independent Director
Gail Farfel, Director
James DVM, CEO, CoFounder
Norman MD, Chief Officer
Keith MBA, Commercial Development
David Hoffmann, Lead Independent Director
Terrence Blaschke, Independent Director
Timothy MBA, CFO Secretary
WeiQi MD, Executive Scientist
Judy Joice, Sr. VP of Operations and Corporate Quality Assurance
Michael Arenberg, CFO
Jian MBA, Senior Officer
Su Yum, Executive Officer
James Brown, President CEO, Director
Armand Neukermans, Independent Director
Felix Theeuwes, Chairman of the Board, Chief Scientific Officer
Andrew Miksztal, VP Scientist
Judith Robertson, Director
Jon Saxe, Independent Director
Jay Shepard, Director
Myriam Theeuwes, Senior Vice President - Clinical Development
Matthew Hogan, CFO
Steve JD, VP Counsel

Durect Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Durect a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Durect

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Durect position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Durect will appreciate offsetting losses from the drop in the long position's value.

Moving together with Durect Stock

  0.85EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against Durect Stock

  0.9MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.88MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.87KA Kineta Inc Report 29th of March 2024 PairCorr
  0.83DBVT DBV Technologies Financial Report 2nd of May 2024 PairCorr
  0.8VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
The ability to find closely correlated positions to Durect could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Durect when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Durect - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Durect to buy it.
The correlation of Durect is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Durect moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Durect moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Durect can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Durect offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Durect's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Durect Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Durect Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Durect. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Durect Stock please use our How to Invest in Durect guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Durect Stock analysis

When running Durect's price analysis, check to measure Durect's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Durect is operating at the current time. Most of Durect's value examination focuses on studying past and present price action to predict the probability of Durect's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Durect's price. Additionally, you may evaluate how the addition of Durect to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
CEOs Directory
Screen CEOs from public companies around the world
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Global Correlations
Find global opportunities by holding instruments from different markets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is Durect's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Durect. If investors know Durect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Durect listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.53)
Revenue Per Share
0.374
Quarterly Revenue Growth
(0.85)
Return On Assets
(0.43)
Return On Equity
(1.49)
The market value of Durect is measured differently than its book value, which is the value of Durect that is recorded on the company's balance sheet. Investors also form their own opinion of Durect's value that differs from its market value or its book value, called intrinsic value, which is Durect's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Durect's market value can be influenced by many factors that don't directly affect Durect's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Durect's value and its price as these two are different measures arrived at by different means. Investors typically determine if Durect is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Durect's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.